Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, for gross proceeds of up to $750. The offering, approved by shareholders on September 26, 2025, is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz. Upon completion, the voting rights attached to the Class A shares will increase to 75.27%, restoring them to nearly their original level when the company went public in 2018. Proceeds will be used for general working capital.
This move is significant as it reinforces the control of the company's founders and early backers, ensuring strategic continuity. Quantum BioPharma focuses on treatments for neurodegenerative, metabolic, and alcohol misuse disorders. Its lead compound, Lucid-MS, is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models of multiple sclerosis. The company also holds a 20.11% stake in Unbuzzd Wellness Inc., which markets the OTC version of unbuzzd, and is entitled to royalty payments: 7% of sales until $250 million is reached, then 3% in perpetuity.
The private placement underscores the company's need for working capital while aligning voting power. Investors should monitor how this governance structure supports Quantum BioPharma's pipeline development and strategic investments through its subsidiary FSD Strategic Investments Inc. The full press release can be viewed at https://ibn.fm/aicDo. For the latest news and updates, visit the company’s newsroom at https://ibn.fm/QNTM.
The announcement highlights the importance of maintaining founder control in biotech firms, where long-term vision is critical. As Quantum BioPharma advances its drug candidates and manages its investment portfolio, the restored voting power ensures that strategic decisions remain aligned with the original vision.
